Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Capecitabine in ER-positive HER2-negative breast cancer with molecular residual disease

Phase 2 trial whose registry primary outcome is the ctDNA clearance rate at 16 weeks of metronomic capecitabine, measured with the Pathlight assay, in people with molecular residual disease. ClinicalTrials.gov lists the study as recruiting.

University Health Network, Toronto